GENE ONLINE|News &
Shanghai Startup Poised for $325M IPO on Nasdaq
With just 2 years into operation, Shanghai startup LianBio is set to go public on the Nasdaq. The firm release the term for the initial public offering (IPO) on Oct. 20, and it plans to raise $325 million to complete Phase 3 clinical trials of its lead drug candidates.
LianBio said it will launch 20 million shares with $15 to $17 per share and a 30-day option to purchase up to an additional 3 million shares.
LianBio said it will launch 20 million shares with $15 to $17 per share and a 30-day option to purchase up to an additional 3 million shares.
GO Prime with only $1.49 now
LATEST
CellTech Accelerator and Cyto-Facto Inc. Forge Strategic Partnership to Advance CGT Industry Growth
2024-04-29
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
